A Novel Prognostic Metric Resolves the MYCN enigma in Silico and Points to a Biosynthetic Regulatory Shift Driven by MYCN Amplification in Neuroblastoma
Matteo Italia, Melody J Parker, Rory Deignan, Fabio Dercole, Dawn Walker, Kenneth Y. Wertheim
This paper introduces a prognostic metric, p53/MYCN, to explain the non-monotonic relationship between MYCN expression and clinical outcomes in neuroblastoma through computational modeling and simulations.
bioRxiv · Nov 13, 2025 · PreprintSystems Biology